Quetiapine Fumarate (Seroquel) as Mono-Therapy or Adjunct to Lithium in the Treatment of Patients With Acute Mania in Bipolar Disorder (MANIA)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00672490
First received: May 2, 2008
Last updated: June 11, 2012
Last verified: June 2012
  Purpose

To compare the efficacy and safety of quetiapine fumarate given as mono-therapy or adjunct therapy to lithium in the treatment of patients with acute mania in bipolar disorder. Patients with a documented clinical diagnosis of bipolar mania according to DSM-IV criteria (296.4X Bipolar I Disorder, Most Recent Episode Manic; 296.0X Bipolar I Disorder, Single Manic Episode) are required to have a YMRS total score of ≥20 at enrolment and randomisation


Condition Intervention Phase
Acute Mania in Bipolar Disorder
Drug: Quetiapine Fumarate
Drug: Lithium
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open Label, 4-Week, Randomised, Multi-Centre, Phase IV Study to Compare the Efficacy and Safety of Quetiapine Fumarate (Seroquel) as Mono-Therapy or Adjunct to Lithium in the Treatment of Patients With Acute Mania in Bipolar Disorder

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Change in the Young Mania Rating Scale (YMRS) Total Score From Baseline to Final Assessment (Day 28) [ Time Frame: Baseline and 4 weeks ] [ Designated as safety issue: No ]
    The YMRS total score ranges from 0 to 60 where higher scores indicate more severe mania, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in manic symptoms. Total score ≤12 indicates remission (13-19=minimal symptoms; 20-25=mild mania, 26-37=moderate mania, 38-60=severe mania).


Secondary Outcome Measures:
  • Change From Baseline in the Clinical Global Impressions for Bipolar Disorder Severity of Illness (CGI-BP-S) Score to Each Assessment (Day 28) [ Time Frame: Baseline and 4 weeks ] [ Designated as safety issue: No ]
    The CGI-BP-S scale rates the severity of the patient's illness at the time of assessment and is scored from 1 to 7 (1=normal, not ill to 7=very severely ill). Higher CGI-BP-S scores indicate greater illness severity

  • Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score to Each Assessment (Day 28) [ Time Frame: Baseline and 4 weeks ] [ Designated as safety issue: No ]
    The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia and each item is rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score is the sum of all 30 individual-item scores and ranges from 30 to 210

  • Change From Baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score to Each Assessment(Day 28) [ Time Frame: Baseline and 4 weeks ] [ Designated as safety issue: Yes ]
    The MADRS is a 10-item scale that evaluates depressive symptoms. Each MADRS item is rated on a 0 to 6 scale. Higher MADRS scores indicate higher levels of depressive symptoms. The MADRS total score is the sum of all 10 individual-item scores and ranges from 0 to 60.

  • Change From Baseline in the Young Mania Rating Scale (YMRS) Item 4 Score to Each Assessment [ Time Frame: Baseline and 4 weeks ] [ Designated as safety issue: No ]
    The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4 (0=normal). This analysis is for Item 4 (sleep) which ranges from 0 to 4 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.

  • Response Rate (Number of Patients With Clinically Response) [ Time Frame: From Baseline to 4 weeks ] [ Designated as safety issue: No ]
    The number of patients with clinically response (defined as ≥50% reduction in the YMRS total score from baseline to Day 28) was calculated. The YMRS total score ranges from 0 to 60 where higher scores indicate more severe mania, thus, a negative change (or 50% reduction) from baseline indicates a reduction (or improvement) in manic symptoms.

  • Remission Rate (Number of Patients With Clinically Significant Remission) [ Time Frame: From Baseline to 4 weeks ] [ Designated as safety issue: No ]

    The number of patients with clinically significant remission (defined as YMRS total score ≤12) at Day 28 was calculated.

    The YMRS total score ranges from 0 to 60 where higher scores indicate more severe mania. Total score ≤12 indicates remission.


  • Treatment of Agitation (Change From Baseline in the PANSS Activation Subscale Score to Day 28) [ Time Frame: Baseline and 4 weeks ] [ Designated as safety issue: No ]
    The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia and each item is rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS activation subscale score for effect on agitation and aggression is the sum of 6 PANSS individual items (ie, hostility, poor impulse control, excitement, uncooperativeness, poor rapport and tension) and ranges from 6 to 42.

  • Treatment of Aggression Risk (Change From Baseline in the PANSS Supplement Aggression Risk Subscale Score to Day 28) [ Time Frame: Baseline and 4 weeks ] [ Designated as safety issue: No ]
    The PANSS Supplemental Aggression Risk subscale score is the sum of 3 standard PANSS items - Excitement, Hostility and Depression - and 3 supplemental PANSS items related to anger - Anger, Difficulty in Delaying Gratification and Affective Lability and ranges from 6 to 42, where 6 is the "best" and 42 the "worst" score for the combined scale.


Enrollment: 376
Study Start Date: April 2008
Study Completion Date: July 2009
Primary Completion Date: July 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Quetiapine Fumarate - tablets
Drug: Quetiapine Fumarate

Oral treatment, twice daily. 100 mg/day at Day 1, 200 mg/day at Day 2, 300 mg/day at Day 3, 400 mg/day at Day 4, from 400 mg/day to 600 mg/day before Day 8, from 600 mg/day to 800 thereafter, judged by the investigator.

Tablets

Other Name: Seroquel
Experimental: 2
Quetiapine Fumarate - tablets and Lithium
Drug: Quetiapine Fumarate

Oral treatment, twice daily. 100 mg/day at Day 1, 200 mg/day at Day 2, 300 mg/day at Day 3, 400 mg/day at Day 4, from 400 mg/day to 600 mg/day before Day 8, from 600 mg/day to 800 thereafter, judged by the investigator.

Tablets

Other Name: Seroquel
Drug: Lithium
Oral treatment, twice daily. 250 mg/day to 2000mg/day from Day1 to Day 7, 500mg/day to 2000mg/day thereafter, judged by the investigator.

  Eligibility

Ages Eligible for Study:   18 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Provision of written informed consent before initiation of any study related procedures. Patients who are deemed incapable of providing informed consent maybe enrolled if written informed consent has been obtained from the patient's Legally Authorized Representative.
  • Documented clinical diagnosis meeting the DSM-IV criteria for any of the following:
  • 296.4X Bipolar I Disorder, Most Recent Episode Manic
  • 296.0X Bipolar I Disorder, Single Manic Episode
  • Have a YMRS score of at least 20 and a score of at least 4 on 2 of the following 4 YMRS items both at enrolment and at randomisation: Irritability, Speech, Content, and Disruptive/Aggressive Behaviour.
  • Female patients of childbearing potential must have a negative urine pregnancy test at enrolment and be willing to use a reliable method of birth control, i.e., barrier method, oral contraceptive, implant, dermal contraception, long-term injectable contraceptive, intrauterine device, or tubal ligation, during the study.
  • Be able to understand and comply with the requirements of the study, as judged by the investigator.

Exclusion Criteria:

  • Manic episode judged to be either:
  • the direct physiological consequence of a treatment or medical condition other than Bipolar disorder.
  • the direct physiological effect of a substance of abuse; intoxication with hallucinogens, inhalants, opioids, or phencyclidine and related substances.
  • the direct physiological effect of psychostimulant or antidepressant medication.
  • Evidence of clinically severe or active disease, or a clinical finding that is unstable or that, in the opinion of the investigator, would be negatively affected by the study medication or that would affect the study medication.
  • History of seizure disorder, except febrile convulsions.
  • Hospitalization period of 3 weeks or longer immediately prior to randomization for the index manic episode.
  • Known history of intolerance or hypersensitivity to quetiapine or lithium, or to any other component in the tablets/capsules.
  • Known lack of response to quetiapine or lithium, as judged by the investigator.
  • Use of antipsychotic medication or mood stabilizer other than quetiapine and lithium at the day of randomisation (to be tapered to discontinuation between the enrolment visit and randomisation).
  • Administration of a depot antipsychotic injection within 1 dosing interval (for the depot) before randomisation.
  • Use of clozapine within 28 days prior to randomisation.
  • Use of antidepressants during the enrolment period or within a period of 5 half-lives of the drug(s) prior to randomisation.
  • Continuous daily use of benzodiazepines in excess of 4 mg per day of lorazepam, or the equivalent, during 28 days prior to randomisation.
  • Use of drugs that induce or inhibit the hepatic metabolizing cytochrome 3A4 enzymes within 14 days before randomisation.
  • Receipt of electroconvulsive therapy (ECT) within 28 days prior to randomisation.
  • Clinically significant deviation from the reference range in clinical laboratory test results at enrolment, as judged by the investigator.
  • An absolute neutrophil count (ANC) of <1.5X109/L.
  • Treatment with quetiapine with a dosage of at least 50 mg/day at enrolment (Visit 1)
  • Liver function test AST or ALT 2 times as the upper normal limit.
  • A thyroid-stimulating hormone (TSH) concentration more than 10% above the upper limit of the normal range of the laboratory used for sample analysis at enrolment, whether or not the subject is being treated for hypothyroidism.
  • Known diagnosis of Diabetes Mellitus (DM) or fasting blood glucose level > the upper normal limit.
  • Risk of transmitting human immuno-deficiency virus (HIV) or hepatitis B via blood or other body fluids, as judged by the investigator.
  • ECG results considered to be clinically significant as determined by the investigator.
  • Conditions that could affect absorption and metabolism of study medication.
  • Patients who in the investigators opinion will require systematic psychotherapy (other than supportive psychotherapy) during the study period.
  • Participation in another clinical study or compassionate use programme within 28 days prior to randomisation, or longer if locally required.
  • Involvement in the planning and conduct of the study (applies to all AstraZeneca or staff at the investigational site).
  • Previous enrolment or randomisation of treatment in the present study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00672490

Locations
China, Beijing
Research Site
Beijing, Beijing, China
China, Guangdong
Research Site
Guangzhou, Guangdong, China
China, Hebei
Research Site
Baoding, Hebei, China
Research Site
Shijiazhuang, Hebei, China
China, Heilongjiang
Research Site
Daqing, Heilongjiang, China
China, Henan
Research Site
Xinxiang, Henan, China
China, Hubei
Research Site
Wuhan, Hubei, China
China, Jiangsu
Research Site
Suzhou, Jiangsu, China
China, Liaoning
Research Site
Shenyang, Liaoning, China
China, Shanghai
Research Site
Shanghai, Shanghai, China
China, Shanxi
Research Site
Xijing, Shanxi, China
China, Sichuan
Research Site
Chengdu, Sichuan, China
China, Tianjin
Research Site
Tianjin, Tianjin, China
China, Yunnan
Research Site
Kuming, Yunnan, China
China, Zhejiang
Research Site
Hangzhou, Zhejiang, China
Research Site
Huzhou, Zhejiang, China
Sponsors and Collaborators
AstraZeneca
Investigators
Principal Investigator: Zhang Hongyan, Prof. Peking University 6th hospital
  More Information

No publications provided

Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT00672490     History of Changes
Other Study ID Numbers: D1443L00023
Study First Received: May 2, 2008
Results First Received: June 24, 2010
Last Updated: June 11, 2012
Health Authority: China: Food and Drug Administration

Keywords provided by AstraZeneca:
Acute Mania
Bipolar Disorder
Quetiapine Fumarate
Lithium

Additional relevant MeSH terms:
Bipolar Disorder
Affective Disorders, Psychotic
Mood Disorders
Mental Disorders
Lithium
Quetiapine
Lithium Carbonate
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Psychotropic Drugs
Antimanic Agents
Antidepressive Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on August 28, 2014